These mitogenic roles can explain why abnormal activation of the canonical SHH signalling pathway, either through activating mutations in pathway components or by ligand production in an autocrine mechanism, predisposes to cancer in many different tissues, including medulloblastoma, glioblastoma and basal cell carcinoma [93–95]. This evidence concerns the gene SHH and cancer.